These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10916046)

  • 1. [ What drug strategies are advisable for patients with advanced-stage Parkinson's].
    Brefel-Courbon C
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():120-59. PubMed ID: 10916046
    [No Abstract]   [Full Text] [Related]  

  • 2. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dopa-therapy in the treatment of early stage Parkinson's disease].
    Broussolle E
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():91-7. PubMed ID: 10916042
    [No Abstract]   [Full Text] [Related]  

  • 6. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

  • 7. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease A short commentary.
    Quinn NP
    J Neurol; 2003 Jan; 250(1):97. PubMed ID: 12528000
    [No Abstract]   [Full Text] [Related]  

  • 8. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments for Parkinson's disease.
    Health News; 2000 Jun; 6(6):8. PubMed ID: 10865523
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 11. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for Parkinson's disease.
    Med Lett Drugs Ther; 1976 Dec; 18(27):117-8. PubMed ID: 1004371
    [No Abstract]   [Full Text] [Related]  

  • 13. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 14. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa and the progression of Parkinson's disease.
    Walton-Hadlock JL
    N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
    [No Abstract]   [Full Text] [Related]  

  • 17. [Parkinson's disease: what therapeutic strategy is advisable in early stage disease?].
    Destee A
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():109-18. PubMed ID: 10916045
    [No Abstract]   [Full Text] [Related]  

  • 18. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa therapy for Parkinson's disease: challenges and future prospects.
    Olanow CW; Lees A; Obeso J
    Mov Disord; 2008; 23 Suppl 3():S495-6. PubMed ID: 18781670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.